Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)

E Despierre; I Vergote; R Anderson; C Coens; D Katsaros; FR Hirsch; B Boeckx; M Varella-Garcia; A Ferrero; I Ray-Coquard; JA Green; C Steer; Els Berns; A Casado; D Lambrechts; A Jimeno

doi:10.1007/s11523-016-0433-x

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)

E Despierre
, I Vergote
, R Anderson
, C Coens
, D Katsaros
, FR Hirsch
, B Boeckx
, M Varella-Garcia
, A Ferrero
, I Ray-Coquard
, JA Green
, C Steer
, Els Berns
, A Casado
, D Lambrechts
, A Jimeno

Medical Oncology

Research output: Contribution to journal › Article › Academic

2 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	429-429
Number of pages	1
Journal	Targeted Oncology
Volume	11
Issue number	3
DOIs	https://doi.org/10.1007/s11523-016-0433-x
Publication status	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC MM-03-86-01

Access to Document

10.1007/s11523-016-0433-x

Cite this

Despierre, E., Vergote, I., Anderson, R., Coens, C., Katsaros, D., Hirsch, FR., Boeckx, B., Varella-Garcia, M., Ferrero, A., Ray-Coquard, I., Green, JA., Steer, C., Berns, E., Casado, A., Lambrechts, D., & Jimeno, A. (2016). Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015). Targeted Oncology, 11(3), 429-429. https://doi.org/10.1007/s11523-016-0433-x

@article{e2bd20bafda6423db1104d142e4dddc9,

title = "Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)",

author = "E Despierre and I Vergote and R Anderson and C Coens and D Katsaros and FR Hirsch and B Boeckx and M Varella-Garcia and A Ferrero and I Ray-Coquard and JA Green and C Steer and Els Berns and A Casado and D Lambrechts and A Jimeno",

year = "2016",

doi = "10.1007/s11523-016-0433-x",

language = "Undefined/Unknown",

volume = "11",

pages = "429--429",

journal = "Targeted Oncology",

issn = "1776-2596",

publisher = "Adis",

number = "3",

}

Despierre, E, Vergote, I, Anderson, R, Coens, C, Katsaros, D, Hirsch, FR, Boeckx, B, Varella-Garcia, M, Ferrero, A, Ray-Coquard, I, Green, JA, Steer, C, Berns, E, Casado, A, Lambrechts, D & Jimeno, A 2016, 'Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)', Targeted Oncology, vol. 11, no. 3, pp. 429-429. https://doi.org/10.1007/s11523-016-0433-x

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015). / Despierre, E; Vergote, I; Anderson, R et al.
In: Targeted Oncology, Vol. 11, No. 3, 2016, p. 429-429.

Research output: Contribution to journal › Article › Academic

TY - JOUR

T1 - Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)

AU - Despierre, E

AU - Vergote, I

AU - Anderson, R

AU - Coens, C

AU - Katsaros, D

AU - Hirsch, FR

AU - Boeckx, B

AU - Varella-Garcia, M

AU - Ferrero, A

AU - Ray-Coquard, I

AU - Green, JA

AU - Steer, C

AU - Berns, Els

AU - Casado, A

AU - Lambrechts, D

AU - Jimeno, A

PY - 2016

Y1 - 2016

U2 - 10.1007/s11523-016-0433-x

DO - 10.1007/s11523-016-0433-x

M3 - Article

C2 - 27056749

SN - 1776-2596

VL - 11

SP - 429

EP - 429

JO - Targeted Oncology

JF - Targeted Oncology

IS - 3

ER -

Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR et al. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015). Targeted Oncology. 2016;11(3):429-429. doi: 10.1007/s11523-016-0433-x